Seizures related to pregnancy (eclampsia)
Also known as: Eclampsia
Methodology & AI Transparency ⓘ
Seizures related to pregnancy (eclampsia) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Designated in federal medical registries as O15.9, Seizures related to pregnancy (eclampsia) (also termed Eclampsia) falls under Epilepsy & Seizures management, where drug-interaction review [Seizures related to pregnancy (eclampsia) O15.9] establishes baseline severity and rules out diagnostic mimics.
- 2 Real-world patient consensus: Clinical coding for Seizures related to pregnancy (eclampsia) uses ICD-10 O15.9 across Epilepsy & Seizures specialty care.
- 3 Typical cash cost range: Workup highlights for Seizures related to pregnancy (eclampsia) (O15.9): drug-interaction review [Seizures related to pregnancy (eclampsia) O15.9].
- 4 Top reported side effects / signs: Longitudinal Seizures related to pregnancy (eclampsia) monitoring tracks Antiseizure Medication Trough in Seizures related to pregnancy (eclampsia) (O15.9: Level) toward Agent-specific therapeutic window (O15.9).
Ask our AI Specialists anything about Seizures related to pregnancy (eclampsia)
What Is Seizures related to pregnancy (eclampsia)?
Designated in federal medical registries as O15.9, Seizures related to pregnancy (eclampsia) (also termed Eclampsia) falls under Epilepsy & Seizures management, where drug-interaction review [Seizures related to pregnancy (eclampsia) O15.9] establishes baseline severity and rules out diagnostic mimics.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Seizures related to pregnancy (eclampsia) (O15.9) center on thalamocortical network synchronization in Seizures related to pregnancy (eclampsia) (O15.9: or focal structural/metabolic). targeted epilepsy & seizures interventions aim to normalize Antiseizure Medication Trough in Seizures related to pregnancy (eclampsia) (O15.9: Level).
Common Symptoms & Clinical Signs
- • Presentation of Seizures related to pregnancy (eclampsia) (O15.9): unexplained tongue biting, in Seizures related to pregnancy (eclampsia) (O15.9: nocturnal awakening with)
- • Secondary Seizures related to pregnancy (eclampsia) clinical sign: transient episodes of in Seizures related to pregnancy (eclampsia) (O15.9: staring, impaired awareness,)
- • Symptom flares in Seizures related to pregnancy (eclampsia) correlating with Antiseizure Medication Trough in Seizures related to pregnancy (eclampsia) (O15.9: Level) deviation outside Agent-specific therapeutic window (O15.9)
- • Functional epilepsy & seizures impact requiring drug-interaction review [Seizures related to pregnancy (eclampsia) O15.9] evaluation (O15.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Seizures related to pregnancy (eclampsia) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | O15.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Epilepsy & Seizure Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Antiseizure Medication Trough in Seizures related to pregnancy (eclampsia) (O15.9: Level) | Agent-specific therapeutic window (O15.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Seizures related to pregnancy (eclampsia) (O15.9: Sodium/Mg Panel) | Na+ 137–143 mEq/L; Mg 2.0–2.4 mg/dL (O15.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Electroencephalogram (EEG) [Seizures related to pregnancy (eclampsia) O15.9] | Absence of epileptiform discharges (O15.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Seizures related to pregnancy (eclampsia)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nurtec ODT (Rimegepant Sulfate) Nurtec ODT • RxCUI 2282320 | Calcitonin Gene-related Peptide Receptor Antagonist | 74% | $128.6613 | $ 640.00 /mo |
| Clobazam Sympazan, Onfi • RxCUI 1366192 | Benzodiazepine | 84% | $0.1530 | $ 14.70 /mo |
| Stiripentol Diacomit • RxCUI 2054973 | FDA Prescription Therapeutic Agent | 78% | $0.5600 | $ 31.18 /mo |
| Atogepant Qulipta • RxCUI RXN-00747096-3064 | Calcitonin Gene-related Peptide Receptor Antagonist | 88% | $36.5760 | $ 185.00 /mo |
| Denosumab Bilprevda, Ospomyv • RxCUI 2723338 | RANK Ligand Inhibitor | 81% | $812.8408 | $ 185.00 /mo |
| Cannabidiol Epidiolex • RxCUI 2058900 | Cannabinoids | 77% | $1.7500 | $ 79.38 /mo |
| Eptinezumab-Jjmr Vyepti • RxCUI RXN-67386130-2969 | Calcitonin Gene-related Peptide Antagonist | 76% | $2.5400 | $ 111.37 /mo |
| Banzel (Rufinamide) Banzel • RxCUI 824295 | Seizures Agent | 85% | $12.5976 | $ 26.28 /mo |
| Indocyanine Green and Water Indocyanine Green and Water Generic • RxCUI RXN-73624424-1775 | FDA Prescription Therapeutic Agent | 94% | $2.4700 | $ 108.54 /mo |
| Rufinamide Banzel • RxCUI 1092357 | Seizures Agent | 80% | $0.2021 | $ 26.28 /mo |
| Rimegepant Sulfate Nurtec ODT • RxCUI 2282313 | Calcitonin Gene-related Peptide Receptor Antagonist | 77% | $128.6613 | $ 185.00 /mo |
| Zavegepant Zavzpret • RxCUI RXN-63539135-2789 | Calcitonin Gene-related Peptide Receptor Antagonist | 83% | $189.7900 | $ 185.00 /mo |
| Ubrelvy (Ubrogepant) Ubrelvy • RxCUI RXN-B00236501 | Calcitonin Gene-related Peptide Receptor Antagonist | 88% | $103.9888 | $ 640.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Seizures related to pregnancy (eclampsia))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Long-term real-world benefits and safety of adjunctive perampanel in patients: What a 704-Participant Study Found The Intent-to-Treat Analysis Set included 704 patients (529 received perampanel and 175 received placebo during the Core Study; all patients received perampanel during OLEx). Epilepsia open • 2024-04-15 • Phase III Randomized Trial | N = 704 | 93/100 | PMID 37867420 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term effects of adjunctive eslicarbazepine acetate in adult Asian patients In summary, adult Asian patients with refractory focal seizures were responsive to treatment with ESL as add-on treatment and generally showed treatment tolerance well for up to 3 years. Clinical and translational science • 2024-05-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38787305 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of adjunctive perampanel in patients with focal seizures or 128 patients (placebo, n = 39; perampanel, n = 89) were included in the gold-standard blind Safety Analysis Set and 126 (FS, n = 113 [placebo, n = 32; perampanel, n = 81]; FBTCS, n = 35 [placebo, n = 14; perampanel, n = 21];... Epilepsia open • 2021-03-15 • Phase III Randomized Trial | N = 39 | 88/100 | PMID 33681652 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of perampanel in patients with seizures associated with Seventy patients were randomized into the Core Study (perampanel, n = 34; placebo, n = 36), and 58 entered the Extension. Epilepsia • 2025-02-15 • Phase III Randomized Trial | N = 34 | 88/100 | PMID 39576191 ↗ |
| New Insights on Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis: What a 201-Participant Study Found Of 201 patients who completed the randomized phase, 199 (99%) entered the OLE. Epilepsia • 2022-02-15 • Phase III Randomized Trial | N = 201 | 88/100 | PMID 34957550 ↗ |
Seizures related to pregnancy (eclampsia) Patient Community & “People Like Me” Threads
Filter Seizures related to pregnancy (eclampsia) community threads and patient logs by age, biological sex, dosage, and treatment duration.